VANCOUVER, Wash. and NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq:ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by pedigreed biotech industry executives, focused on discovery and development of antibody-drug-conjugates (ADCs) initially for oncology indications. The partner company has developed novel, proprietary warhead linker chemistries that it will target to specified sites on subject antibodies by exploiting Absci’s Bionic Protein™ non-standard amino acid (nsAA) incorporation technology.
Absci Enters Multi-Program Collaboration with Emerging Biotech Partner
Globe Newswire -
Thu Jul 7, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Palantir%20by%20rblfmr%20via%20Shutterstock.jpg)
/Drone%20flying%20by%20Pexels%20via%20Pixabay.jpg)